Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 66Histone Deacetylase Inhibitors ResearchComputational Drug Discovery MethodsEnzyme function and inhibition

The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)

Open access
Luo, Yuxiang, Li, Huilin·2020·International Journal of Molecular Sciences

Abstract

Class I histone deacetylases (HDACs) are promising targets for epigenetic therapies for a range of diseases such as cancers, inflammations, infections and neurological diseases. Although six HDAC inhibitors are now licensed for clinical treatments, they are all pan-inhibitors with little or no HDAC isoform selectivity, exhibiting undesirable side effects. A major issue with the currently available HDAC inhibitors is that they have limited specificity and target multiple deacetylases. Except for HDAC8, Class I HDACs (1, 2 and 3) are recruited to large multiprotein complexes to function. Therefore, there are rising needs to develop new, hopefully, therapeutically efficacious HDAC inhibitors with isoform or complex selectivity. Here, upon the introduction of the structures of Class I HDACs and their complexes, we provide an up-to-date overview of the structure-based discovery of Class I HDAC inhibitors, including pan-, isoform-selective and complex-specific inhibitors, aiming to provide an insight into the discovery of additional HDAC inhibitors with greater selectivity, specificity and therapeutic utility.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21228828

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Structures of Food and Drug Administration (FDA)-approved Class I histone deacetylases (HDAC) inhibitors.
Figure 1 Structures of Food and Drug Administration (FDA)-approved Class I histone deacetylases (HDAC) inhibitors.CC BY · PubMed Central
Figure 2 (A) Superposition of the structures of HDAC1–3 (PDB (Protein Data Bank) codes: 5ICN, 4LY1 and 4A69). Significant residue differences are highlighted in cyan (HDAC1 and 2) and magenta (HDAC3). Adapted with permission from Millard 2017 [15]. (B) The active site of HDAC8 (PDB code: 4QA2). Adapted with permission from Chakrabarti 2015 [17]. (C) The foot pocket of HDAC8. Prominent amino-acid side-chain differences between HDAC8 and HDAC1 in the foot pocket are shown. Adapted with permission from Whitehead 2011 [64].
Figure 2 (A) Superposition of the structures of HDAC1–3 (PDB (Protein Data Bank) codes: 5ICN, 4LY1 and 4A69). Significant residue differences are highlighted in cyan (HDAC1 and 2) and magenta (HDAC3). Adapted with permission from Millard 2017 [15]. (B) The active site of HDAC8 (PDB code: 4QA2). Adapted with permission from Chakrabarti 2015 [17]. (C) The foot pocket of HDAC8. Prominent amino-acid side-chain differences between HDAC8 and HDAC1 in the foot pocket are shown. Adapted with permission from Whitehead 2011 [64].CC BY · PubMed Central
Figure 3 Possible mechanism of catalysis by HDAC8. Adapted with permission from Porter 2019 [66].
Figure 3 Possible mechanism of catalysis by HDAC8. Adapted with permission from Porter 2019 [66].CC BY · PubMed Central
Figure 4 (A) Structure of the core NuRD complex (HDAC1/RBBP4/MTA1 (162-546)). Adapted with permission from Millard 2016 [75]. (B) Substructure of the Sin3 complex. Adapted with permission from Banks 2020 [80]. (C) Structure of the CoREST complex. Adapted with permission from Song 2020 [87]. (D) Structure of the MiDAC complex in dimeric form. Adapted with permission from Turnbull 2020 [89]. (E) Structure of the SMRT/NCoR complex. Adapted with permission from Oberoi 2011 [93].
Figure 4 (A) Structure of the core NuRD complex (HDAC1/RBBP4/MTA1 (162-546)). Adapted with permission from Millard 2016 [75]. (B) Substructure of the Sin3 complex. Adapted with permission from Banks 2020 [80]. (C) Structure of the CoREST complex. Adapted with permission from Song 2020 [87]. (D) Structure of the MiDAC complex in dimeric form. Adapted with permission from Turnbull 2020 [89]. (E) Structure of the SMRT/NCoR complex. Adapted with permission from Oberoi 2011 [93].CC BY · PubMed Central
Figure 5 (A) The binding site of inositol phosphate with HDAC3-SMRT complex. The inositol phosphate is shown as a stick model. Adaptedwith permission from Watson 2012 [94]. (B) Relative position of the allosteric site and binding rail on HDAC2. Adapted with permission from Zhou 2017 [96].
Figure 5 (A) The binding site of inositol phosphate with HDAC3-SMRT complex. The inositol phosphate is shown as a stick model. Adaptedwith permission from Watson 2012 [94]. (B) Relative position of the allosteric site and binding rail on HDAC2. Adapted with permission from Zhou 2017 [96].CC BY · PubMed Central
Figure 6 Selective inhibitors of HDAC8.
Figure 6 Selective inhibitors of HDAC8.CC BY · PubMed Central
Figure 7 Selective inhibitors of HDAC1/2.
Figure 7 Selective inhibitors of HDAC1/2.CC BY · PubMed Central
Figure 8 Selective inhibitors of HDAC3.
Figure 8 Selective inhibitors of HDAC3.CC BY · PubMed Central
Figure 9 Specific-complex inhibitors.
Figure 9 Specific-complex inhibitors.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 168 references

Cited by

See all 66

Metadata

Authors
Luo, Y., & Li, H.
Affiliations
Sun Yat-sen University (CN)
Corresponding author
Li, Huilin
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-11-22
Volume
21
Issue
22
Pages
8828
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3108284227
Cited by
62
References
168
Citations by year
2026: 15 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 5 · 2021: 8
FWCI
0.57
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (91953102)
  • Guangdong Nature Science Foundation (2019A1515011265)
  • Fundamental Research Funds for the Sun Yat-sen Universities (19ykzd26)
  • the Pearl River Talent Recruitment Program (2019QN01Y299)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
Keywords
class I histone deacetylases, histone deacetylase inhibitors, structure-based drug design, isoform selectivity, epigenetic therapy, HDAC8, protein complexes, inhibitor specificity
MeSH terms
Animals, Histone Deacetylases, Humans, Protein Conformation, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). https://app.cochat.ai/papers/10.3390/ijms21228828
The paper
Luo, Y., & Li, H. (2020). Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21228828

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.